Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00924196 · ClinicalTrials.gov registry record

Natural History Study of Patients With Neurofibromatosis Type I

A clinical trial of Neurofibromatosis Type 1 and Plexiform Neurofibroma, sponsored by National Cancer Institute (NCI).

Active
Registry status
259
Enrollment target
1
Study location

NCT00924196: Active study of Neurofibromatosis Type 1 and Plexiform Neurofibroma, sponsored by National Cancer Institute (NCI).

NCT00924196 is a study of Neurofibromatosis Type 1 and Plexiform Neurofibroma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 259 participants, above the 145-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (79% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00924196, a study of Neurofibromatosis Type 1 and Plexiform Neurofibroma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
259 participants
Enrollment target
1
Study location

Study Summary

Background: Neurofibromatosis Type 1 (NF1) is a genetic disorder in which patients are at increased risk of developing tumors (usually non-cancerous) of the central and peripheral nervous system. The disease affects essentially every organ system. The natural course of NFI over time is poorly understood. For most patients the only treatment option is surgery. A better understanding of NF1 may be helpful for the design of future treatment studies. Objectives: To evaluate people with NF1 over 10 years in order to better understand the natural history of the disease. To characterize the patient population and to examine how NFI affects patients quality of life and function. Eligibility: Children, adolescents, and adults with NF1. Design: Participants have a comprehensive baseline evaluation including genetic testing, tumor imaging, pain and quality-of-life assessments, and neuropsychological, motor and endocrine evaluations. Patients are monitored every 6 months to every 3 years, depending on their individual findings at the baseline study. Tests may include the following, as appropriate: * Medical history, physical examination and blood tests. * Whole body and face photography to monitor visible deformities. * Neuropsychological testing, quality-of-life evaluations, motor function tests, endocrinologic evaluations, heart and lung function tests, hearing tests, bone density scans and other bone evaluations. * MRI and PET scans to detect and assess plexiform neurofibromas (tumors that arise from nerves and can cause serious problems), paraspinal neurofibromas (tumors that arise from nerves around the spine and can cause problems by compressing the spinal cord), and malignant peripheral nerve sheath tumors (a type of cancer that arises from a peripheral nerve or involves the sheath covering the nerve). * Eye exams, MRI scans and PET scans to evaluate optic pathway gliomas (tumors arising from the vision nerves or the brain areas for vision) and the chemicals w

Primary Outcome

Characterized features will be described and presented.

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 259 participants
Start Date 2008-02-25
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT00924196 still lists

NCT00924196 is an observational study that tracks outcomes without assigning an intervention. The registered 259 participants enrollment target is mid-sized for trials with a published cap, above the 145-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (79% higher).

The record links to 5 conditions, with Neurofibromatosis Type 1 appearing as the primary indexed condition, and to 0 interventions.

NCT00924196 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00924196 about?

NCT00924196 is a clinical study titled "Natural History Study of Patients With Neurofibromatosis Type I". Background: Neurofibromatosis Type 1 (NF1) is a genetic disorder in which patients are at increased risk of developing tumors (usually non-cancerous) of the central and peripheral nervous system. The disease affects essentially every organ system. The natural course of NFI over time is poorly unde...

What is the current status of trial NCT00924196?

This trial is currently active not recruiting. The enrollment target is 259 participants. The study started on 2008-02-25.

What conditions does trial NCT00924196 study?

This clinical trial studies the following conditions: Neurofibromatosis Type 1, Plexiform Neurofibroma, Malignant Peripheral Nerve Sheath Tumor, Neurofibroma, Optic Glioma.

Who is sponsoring clinical trial NCT00924196?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00924196 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neurofibromatosis Type 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00924196's enrollment target sits among peer trials

259 3rd of 17 higher than 15 of 17 other Neurofibromatosis Type 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neurofibromatosis Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02361320 · 259 participants · NA

    Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer

  • NCT06797258 · 259 participants · NA

    FlexHD® Pliable Investigation in Implant-Based Breast Reconstruction

  • NCT06990425 · 259 participants · NA

    CLOSM Trial: Groin Closure Using Layered Option for Suture Material

  • NCT07399977 · 259 participants · NA

    Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00924196, the US trial registry maintained by the National Library of Medicine. NCT00924196 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.